Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

May

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

Deborah Collyar: What's In It for Patients?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer

Dose Escalation of Fluorodeoxyglucose PET Guided Radiotherapy for Locally Advanced NSCLC

Use of CAD CAM May Improve Jaw Reconstruction Outcomes Among Patients With Head and Neck Cancer

Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma

Applications Are Now Open for the 2025 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program